Clinical Trial Update: Secukinumab Drug Survival, Effectiveness and Tolerability in Pediatric Patients With Psoriasis

View source ↗

Summary

Clinical trial update on secukinumab examining drug survival, effectiveness and tolerability in pediatric patients with moderate-to-severe plaque psoriasis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• Cosentyx (secukinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Moderate-to-severe Plaque Psoriasis | Status: ACTIVE_NOT_RECRUITING